Form 4: BioXcel Therapeutics Executive Matthew Wiley Reports Changes in Beneficial Ownership After Departure
SEC Form 4 Filing
Matthew Wiley, former Chief Commercial Officer of BioXcel Therapeutics, reports adjustments to his stock options following his termination of employment.
Summary
- This Form 4 filing details changes in beneficial ownership for Matthew T. Wiley, former Chief Commercial Officer of BioXcel Therapeutics, Inc.
- The filing reports the grant of a stock option to purchase 1,875 shares of common stock on July 22, 2024, at an exercise price of $1.20.
- The stock option was to vest in two equal installments on the first and second anniversaries of the grant date, contingent upon continuous employment.
- Due to Wiley's termination of employment, the unvested portion of the stock option was forfeited.
- The share amount has been adjusted to reflect a 1-for-16 reverse stock split effective February 7, 2025.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document primarily reports a routine adjustment in stock ownership following an executive's departure. There are no indications of significant positive or negative developments for the company.
Negatives
- The unvested portion of Matthew Wiley's stock options was forfeited due to his termination of employment.
Industry Context
Executive departures and associated adjustments to equity compensation are common occurrences in the biopharmaceutical industry. This filing reflects the standard process of reporting such changes to comply with SEC regulations.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Commercial Officer | Matthew Wiley | Termination of employment |
Stakeholder Impact
- Shareholders may be interested in executive compensation and changes in management.
Key Dates
| Date | Description |
|---|---|
| 07/22/2024 | Date of the stock option grant. |
| 02/07/2025 | Effective date of the 1-for-16 reverse stock split. |
| 04/01/2025 | Date of the Form 4 filing. |
Keywords
Form 4, BioXcel Therapeutics, Stock Option, Beneficial Ownership, Executive Compensation, Reverse Stock Split, Wiley, BTAI
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.